NewslettersPulmonary Cell News MERTK Activation Drives Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer By Bob - June 23, 2022 0 Treatment with MRX-2843, a first-in-class MERTK kinase inhibitor, re-sensitized GAS6-treated NSCLC cells to osimertinib. [Journal of Clinical Investigation] AbstractGraphical Abstract